United States Patent 9,352,025: Scope, Claims, and US Patent Landscape for Dopamine Agonist plus “First-Phase” Insulin Secretagogue in Metabolic Disorders
What does US 9,352,025 claim, at the core?
US Patent 9,352,025 is directed to method-of-treatment claims for metabolic disorders (with heavy focus on glucose intolerance, insulin resistance, and type 2 diabetes/prediabetes) using a combination regimen:
- (a) a dopamine receptor agonist to increase central dopaminergic activity; and
- (b) a “first-phase insulin secretagogue” limited to agents intended to drive early insulin secretion (explicitly including GLP-1/analog, DPP-4 inhibitors, GIP, meglitinides (repaglinide, nataglinide), and short-acting insulin).
The claims require non-additive pharmacodynamic effect: the combination must provide a therapeutic effect greater than the additive effect of each component alone at the same dosages.
A second key constraint is circadian-timed dopamine dosing:
- the dopamine agonist is administered so as to increase central dopaminergic activity at the time of day when its circadian rhythm naturally peaks in healthy subjects of the same species; and
- the first-phase insulin secretagogue is administered with an effective amount present daily.
This results in a claim set structured around:
- Agent class selection (dopamine agonists + first-phase insulin secretagogues),
- Dosing regimen structure (timing and daily presence),
- Combination superiority (synergistic, non-additive effect),
- Metabolic indication coverage via broad disease/key-element lists.
What is the independent claim scope (and how broad is it)?
Claim 1 (Independent) key scope elements
Claim 1 covers:
Method of treating:
- “a metabolic disorder or key elements of a metabolic disorder”
Combination:
- dopamine receptor agonist
- first-phase insulin secretagogue from a defined group:
- GLP-1 or analog
- DPP inhibitor
- GIP (“gastric inhibitory polypeptide” / glucose-dependent insulinotropic peptide)
- meglitinide (incl. repaglinide, nataglinide)
- short acting insulin
Combination effect requirement:
- combination effect > additive effect of each drug at the same dosage alone.
Circadian/timing constraints:
- dopamine agonist dosing time matches its central dopaminergic circadian peak (species-specific)
- first-phase secretagogue has effective amount present daily
Claim 19 (Independent) is a broader variant
Claim 19 omits some of the circadian language and changes the dosing requirement:
- dopamine agonist + first-phase insulin secretagogue
- combination effect > additive effect
- both agents administered such that an effective amount of each is present daily (no explicit circadian peak constraint).
Net effect: Claim 19 expands coverage to regimens that still meet the non-additive combination requirement but relaxes the circadian timing specificity found in Claim 1.
Overall breadth summary
From the text you provided, the invention scope is broad because it:
- uses method claims rather than a fixed formulation;
- uses class definitions for both components;
- includes both disease and “key elements” (biomarker/condition features) as treatment targets;
- requires synergy rather than a defined dose, enabling many dosing schedules to be argued if the non-additive effect is met.
How do the dependent claims tighten coverage?
Below are the main dependent claim layers and what they narrow.
Which dopamine agonists are explicitly allowed?
Multiple dependent claims define dopamine receptor agonist subsets.
Claim 2 (D2-biased and low/none serotonin 2B activity):
- bromocriptine
- lisuride
- hydergene
- dihydroergotoxine
- “other dopamine D2 receptor agonists with low or no serotonin 2B receptor agonist activity”
Claim 11 (expanded dopamine agonist set):
- quinpirole
- quinerolane
- talipexole
- ropinirole
- apomorphine
- terguride
- fenoldopam
- dihydroergocryptine
- combinations thereof
Claim 13:
- dopamine agonist can be a combination of D1 agonist + D2 agonist.
Claim 16 and Claim 17 lock a specific dopamine component:
- bromocriptine or pharmaceutically acceptable salt
- Claim 17 specifies mesylate salt.
How is the first-phase insulin secretagogue defined?
The shared limitation across Claim 1/14/19 is a defined menu. Dependent claims do not materially shrink the secretagogue universe beyond using:
- GLP-1/analog and/or insulin in certain bromocriptine-specific claims (Claim 16), and
- explicit inclusion of meglitinides and short acting insulin in the general set.
What timing and dosing constraints exist?
- Claim 6: dopamine agonist within 4 hours of waking in the morning.
- Claim 7: dopamine agonist within 2 hours of waking.
- Claim 8-10: dose-limitation logic:
- Claim 8: dopamine dose is insufficient alone
- Claim 9: secretagogue dose insufficient alone
- Claim 10: combination effective
These claims are practical for enforcement because they define the regimen logic as “insufficient alone, sufficient together,” which supports arguments based on dose-response data.
How do the indications expand?
Claim 3 includes:
- pre-diabetes
- Impaired Fasting Glucose (IFG)
- Impaired Glucose Tolerance (IGT)
- Type 2 diabetes
Claim 4 expands to:
- metabolic syndrome
- obesity
- insulin resistance
- hyperinsulinemia
- cardiovascular disease
- elevated plasma norepinephrine
- inflammatory factors potentiating vascular endothelial dysfunction
- hyperlipoproteinemia
- atherosclerosis
- coronary artery disease
- peripheral vascular disease
- congestive heart failure
- hepatic steatosis
- renal disease including renal insufficiency
- cerebrovascular disease
- plus additional clinical states: hyperphagia, hyperglycemia, hyperlipidemia, hypertension, etc.
Claim 5 is a “key elements” biomarker/condition list including:
- impaired fasting glucose/GT
- waist circumference and visceral fat
- fasting glucose/triglycerides/free fatty acids
- HDL reduction
- systolic/diastolic BP elevations
- postprandial TG/FFA elevations
- oxidative stress indicators
- hypercoagulative state
- arteriosclerosis and vascular diseases
- hepatic steatosis, renal insufficiency
- cerebrovascular disease
Bottom line: the patent is not a single narrow metabolic claim. It is a platform-like combination regimen asserted across metabolic syndrome and vascular-risk features.
What do Claims 14-18 cover (broad glucose intolerance/IR variants)?
Claim 14
Method for glucose intolerance or insulin resistance in a mammal with:
- dopamine D2 receptor agonist:
- bromocriptine, lisuride, hydergene, dihydroergotoxine, or other D2 agonists with low/no serotonin 2B activity
- first-phase insulin secretagogue:
- GLP-1/analog, DPP inhibitor, GIP, meglitinides, repaglinide/nataglinide, short acting insulin
Same regimen logic:
- non-additive effect
- dopamine administered at circadian peak time
- secretagogue daily effective amount
Claim 16 and 19 relationship
Claim 16 narrows dopamine to:
and narrows secretagogue set to:
- GLP-1/analog and insulin (not the full secretagogue menu)
Claim 18 narrows indication:
- mammal suffering from type 2 diabetes
Claim 17 adds:
Claim 19
An independent variant that overlaps Claim 1 but drops the circadian timing requirement and only requires daily effective amounts for both agents.
What is the enforcement-relevant claim architecture?
Three claim hooks drive enforceability:
-
Combination synergy requirement
- “therapeutic effect greater than the additive effect” at the same dosages each alone.
This shifts the infringement debate toward comparative pharmacology.
-
Defined “first-phase” insulin secretagogue menu
- The patent targets specific classes and explicitly includes short-acting insulin, GLP-1/analogs, DPP inhibitors, GIP, and meglitinides.
-
Circadian central dopaminergic timing
- In Claims 1 and 6-7, dopamine dosing aligns to the dopamine circadian peak relative to waking.
This structure means the most robust infringement argument likely pairs:
- a dopamine agonist dosed at a circadian-peak window, and
- a GLP-1/DPP-4/GIP/meglitinide/short-acting insulin regimen that creates early insulin secretion.
Where does US 9,352,025 sit in the US patent landscape (strategic implications)?
1) Interaction with established metabolic drug IP
The claim space intersects widely used therapeutic classes:
- GLP-1 receptor agonists and GLP-1 analogs
- DPP-4 inhibitors (as DPP inhibitors)
- GIP and related incretin-based agents
- meglitinides (repaglinide, nataglinide)
- short-acting insulin
Those classes are heavily patented. US 9,352,025 is not a composition claim for those drugs; it is a combination-use method claim with a synergy requirement and timing constraints.
Practical reading: even if the partner drug is off-patent or widely licensed, the claimed combination regimen can remain actionable if the superiority and dosing logic are met.
2) Dopamine agonist IP overlap
Dopamine agonists include:
- older ergot-derived D2 agonists (bromocriptine class; lisuride; dihydroergotoxine; etc.)
- non-ergot dopaminergics (ropinirole, apomorphine, quinpirole, etc.)
- D1/D2 combinations (as a permissible structure)
These are well-established in the market, but in the US landscape they may still have:
- method-of-use patents for circadian dosing
- patient-selection strategies (often tied to psychiatric or Parkinson’s indications)
- formulation-specific IP
US 9,352,025 specifically re-anchors them to metabolic indications with the synergy and early insulin secretagogue timing/dosing requirements.
3) “Platform” combination risk for R&D
The breadth of the secretagogue menu and the list of dopamine agonists create a platform-like risk profile:
- If a development program uses any dopamine agonist to increase central dopaminergic activity and co-administers one of the listed “first-phase” secretagogues with daily effective exposure (and for some claims, circadian peak timing), the program could fall within the method claim framework.
- The synergy requirement is the main differentiator. But synergy can often be engineered and proven through designed preclinical and clinical combination studies.
4) Challenge to “design-around”
Common design-around strategies:
- drop the circadian peak timing element (Claim 19 still covers daily effective amounts)
- use an insulin secretagogue outside the explicit list (the claim menu is broad but not infinite)
- eliminate non-additivity by achieving only additive effect (hard to do if biological synergy exists, and claims require “therapeutic effect greater than additive effect,” which can be argued either way with study design)
Given Claim 19’s relaxation to daily effective amounts, design-around options are constrained: removing circadian dosing does not automatically avoid infringement.
How much of the claim set is anchored to daily dosing vs time-of-day?
Two main regimen structures appear:
-
Circadian peak window structure
- dopamine at circadian peak time (Claims 1, 6-7, 14, 16)
- secretagogue: effective amount present daily
-
Daily effective amounts structure
- both dopamine and secretagogue with daily effective amounts (Claim 19)
This means a competitor must treat Claim 19 as a baseline even if they avoid circadian timing.
Key takeaways for business and IP strategy
- US 9,352,025 is a combination-use claim set: dopamine receptor agonist plus a defined “first-phase insulin secretagogue” menu, with non-additive (synergistic) therapeutic effect as a core limitation.
- The indication scope is broad across diabetes/prediabetes and “key elements” ranging from glucose metrics and obesity measures to cardiovascular and organ-injury features.
- Circadian timing increases risk but does not fully control it: Claim 1-7 emphasize circadian peak dosing, while Claim 19 covers regimens where both agents are present at effective daily amounts.
- Dopamine agent coverage is wide: explicitly includes bromocriptine-class (and other D2 agonists with low/no serotonin 2B activity), plus a longer list of other dopaminergics.
- Synergy is the main litigation lever: infringement and validity arguments will likely turn on whether combination efficacy is demonstrably greater than additive effects at matched dosages.
FAQs
1) What is the essential infringement theory under US 9,352,025?
A method in a treated patient that administers a dopamine receptor agonist plus a listed first-phase insulin secretagogue with dosing such that the combination effect exceeds additive effects at the same dosages and (for some claims) dopamine is timed to a circadian dopaminergic peak.
2) Does the patent require a specific dosage amount or only effective dosages?
The claims are framed around effective amounts and include dependent claims that the component doses are insufficient alone. The primary fixed numeric dosing is not present in the claim text you supplied; the critical requirement is synergy versus additive effect.
3) Which incretin-related agents are explicitly within scope?
GLP-1 or analogs, DPP inhibitors, and GIP (glucose-dependent insulinotropic peptide) are explicitly listed.
4) Can the dopamine agonist be bromocriptine specifically?
Yes. Claim 16 specifies bromocriptine or its pharmaceutically acceptable salt, and Claim 17 specifies mesylate as an example.
5) If a product avoids circadian peak timing, is it still at risk?
Yes. Claim 19 covers methods where both agents are administered such that effective amounts of each are present daily, without requiring the circadian-peak timing element.
References
[1] United States Patent No. 9,352,025 (claims text provided in prompt).
